Cell Impact AB Cash Flow-to-Debt Ratio
Cell Impact AB cash flow-to-debt ratio. Cell Impact AB (CI) has a Cash Flow-to-Debt Ratio of -0.67x as of September 2025, meaning its operating cash flow of Skr-19.56 Million could theoretically repay -1% of its total liabilities (Skr29.21 Million) in one year. See how financially flexible is Cell Impact AB to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Cell Impact AB (2012–2024)
Cash flow-to-debt ratio of Cell Impact AB from 2012 to 2024. Historical debt coverage capacity for Cell Impact AB across 13 annual periods. Check CI total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Cell Impact AB Cash Flow-to-Debt Ratio by Year (2012–2024)
Cell Impact AB cash flow-to-debt ratio by year from 2012 to 2024. Year-by-year debt coverage analysis for Cell Impact AB. For the full cash flow conversion analysis, see CI cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.48x | Skr-62.23 Million | Skr42.16 Million | ▼ -14.8% |
| 2023 | -1.29x | Skr-100.97 Million | Skr78.56 Million | ▲ +6.4% |
| 2022 | -1.37x | Skr-105.93 Million | Skr77.17 Million | ▼ -53.3% |
| 2021 | -0.90x | Skr-86.08 Million | Skr96.10 Million | ▲ +22.9% |
| 2020 | -1.16x | Skr-47.59 Million | Skr40.99 Million | ▲ +63.2% |
| 2019 | -3.16x | Skr-41.01 Million | Skr12.98 Million | ▼ -40.5% |
| 2018 | -2.25x | Skr-42.57 Million | Skr18.94 Million | ▲ +8.2% |
| 2017 | -2.45x | Skr-15.84 Million | Skr6.47 Million | ▼ -204.4% |
| 2016 | -0.80x | Skr-8.92 Million | Skr11.10 Million | ▲ +22.9% |
| 2015 | -1.04x | Skr-5.56 Million | Skr5.33 Million | ▲ +45.1% |
| 2014 | -1.90x | Skr-5.86 Million | Skr3.08 Million | ▲ +21.2% |
| 2013 | -2.41x | Skr-7.86 Million | Skr3.26 Million | ▼ -13.0% |
| 2012 | -2.13x | Skr-7.80 Million | Skr3.66 Million | — |